Cellectis and MabQuest to develop new class of anti-PD-1 mAbs
17 March 2016 | By Victoria White
These anti-PD-1 mAbs have potential uses for multiple indications in immunotherapy, including notably treatments for a variety of cancers...
List view / Grid view
17 March 2016 | By Victoria White
These anti-PD-1 mAbs have potential uses for multiple indications in immunotherapy, including notably treatments for a variety of cancers...
12 January 2016 | By Victoria White
A new study describes the design of a CAR architecture with an integrated switch-on system that permits control over CAR T-cell functions...
4 January 2016 | By Victoria White
UCART19 is a potential best-in-class allogeneic Talen gene edited T-cell product for treatment of CD19 expressing haematological malignancies...